Gene therapy-focused Genetix Pharmaceuticals raises $35 million
15 March 2010
Sukaina Virji
Please Login to read the full article.
15 March 2010
Sukaina Virji
sukaina.virji@informa.com
Genetix Pharmaceuticals, which is developing gene therapies for genetic disorders, has raised $35 million in series B funds. The round included new investors Third Rock Ventures and Genzyme Ventures, with existing investors TVM Capital, Forbion and Easton Capital also participating.
The proceeds...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Mesoblast gains US FDA OK for Phase III mesenchymal precursor cell study
- Stem cell death for cash-crunched Geron, Angiotech, but Mesoblast outlasts them
- Athersys to reshape trial for cell therapy in heart attack after regaining rights
- Mesoblast sees little impact from proposed Valeant/Cephalon deal
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
